Samsca approved in Japan for rare kidney disorder
This article was originally published in Scrip
Otsuka Pharmaceutical's aquaretic agent Samsca (tolvaptan) has received its first approval worldwide, in Japan, for the indication of autosomal dominant polycystic kidney disease (ADPKD).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.